NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
Multiple system atrophy (MSA) is a severe neurodegenerative disorder with various underlying pathophysiological features. Mitochondrial dysfunction has been implied as a viable treatment target in patients with MSA. Yet, there is a lack of in-vivo studies examining regional metabolic differences between the Parkinsonian (MSAp) and the cerebellar (MSAc) subtype of MSA. Twenty-four patients with MSA (12 patients with MSAp and 12 patients with MSAc), 24 patients with Parkinson's disease (PD), and 24 age- and sex-matched healthy controls (HCs) underwent clinical evaluations and multimodal neuroimaging, including 31P-MRSI targeting the basal ganglia and the cerebellum. Ratios of high-energy phosphorus-containing metabolites (HEPs) were compared between groups. Only patients with MSAc showed decreased HEP levels in the cerebellum. Conversely, no differences in basal ganglia HEP levels appeared between both MSA subtypes, patients with PD, or HCs. Our findings provide preliminary in-vivo evidence for regionally detectable bioenergetic alterations in the cerebellum of patients with MSAc, while basal ganglia results, particularly in MSAp, require cautious interpretation because of the spatial-resolution limits of the present 31P-MRSI approach.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.